Clinical Trial

Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis

Study acronym: EVER-ILD 3
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the efficacy on lung function after 24 weeks of rituximab + MMF combination comparatively to placebo + MMF combination in patients with SSc-ILD severe at the initial assessment or at high risk of progression.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-07.
Status change: Not Yet Recruiting → Recruiting 2026-06-10
Trial Details
NCT Number NCT06549231
Lead Sponsor University Hospital, Tours
Conditions Interstitial Lung Disease With Systemic Sclerosis
Enrollment 102 participants
Start Date 2025-01-08
Primary Completion 2028-07-08 (estimated)
Study Completion 2029-01-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-12